Molecular imaging using PET for breast cancer

Breast Cancer. 2016 Jan;23(1):24-32. doi: 10.1007/s12282-015-0613-z. Epub 2015 Apr 28.

Abstract

Molecular imaging can visualize the biological processes at the molecular and cellular levels in vivo using certain tracers for specific molecular targets. Molecular imaging of breast cancer can be performed with various imaging modalities, however, positron emission tomography (PET) is a sensitive and non-invasive molecular imaging technology and this review will focus on PET molecular imaging of breast cancer, such as FDG-PET, FLT-PET, hormone receptor PET, and anti-HER2 PET.

Keywords: Breast cancer; HER2; Molecular imaging; Molecular target therapy; PET.

Publication types

  • Review

MeSH terms

  • Bevacizumab
  • Breast Neoplasms / diagnostic imaging*
  • Breast Neoplasms / metabolism
  • Carcinoma, Ductal, Breast / diagnostic imaging*
  • Carcinoma, Ductal, Breast / metabolism
  • Cetuximab
  • Dideoxynucleosides
  • ErbB Receptors / metabolism
  • Female
  • Fluorine Radioisotopes
  • Fluorodeoxyglucose F18
  • Humans
  • Molecular Imaging / methods*
  • Norprogesterones
  • Positron-Emission Tomography / methods*
  • Radiopharmaceuticals*
  • Receptor, ErbB-2 / metabolism
  • Receptor, IGF Type 1 / metabolism
  • Receptors, Estrogen / metabolism
  • Receptors, Progesterone / metabolism
  • Receptors, Vascular Endothelial Growth Factor / metabolism
  • Trastuzumab

Substances

  • Dideoxynucleosides
  • Fluorine Radioisotopes
  • Norprogesterones
  • Radiopharmaceuticals
  • Receptors, Estrogen
  • Receptors, Progesterone
  • Fluorodeoxyglucose F18
  • Bevacizumab
  • EGFR protein, human
  • ERBB2 protein, human
  • ErbB Receptors
  • Receptor, ErbB-2
  • Receptor, IGF Type 1
  • Receptors, Vascular Endothelial Growth Factor
  • Trastuzumab
  • alovudine
  • Cetuximab